Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 4Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Gemcitabine 3Cyclophosphamide 3romidepsin 2pembrolizumab 2duvelisib 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Biopsy 2Azacitidine 2tazemetostat 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1ruxolitinib 1ixazomib 1ivarmacitinib 1fludarabine 1etoposide phosphate 1cemiplimab 1cabiralizumab 1belinostat 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Specimen Handling 1Prednisolone 1Photons 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × ixazomib × 90 days × Clear all
NCT03547700 2026-05-06

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
11 enrolled 10 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡